Biomerica, Inc. announced that data from its pivotal clinical trial evaluating the inFoods IBS test in treating IBS sufferers has been published in the June 2025 issue of *Gastroenterology*. This journal is the official publication of the American Gastroenterological Association and is recognized as the highest-impact publication in the GI field. The publication reinforces the scientific rigor, statistical significance, and clinical impact of the inFoods IBS approach for treating patients.
The randomized, multicenter, double-blind, placebo-controlled trial included 238 patients across eight U.S. academic centers, including Mayo Clinic, Cleveland Clinic, and the University of Michigan. The study demonstrated that patients with Irritable Bowel Syndrome (IBS) experienced statistically significant improvement in symptoms, particularly abdominal pain and bloating, when following a personalized elimination diet guided by the inFoods IBS test. The test identifies specific foods that provoke an abnormal immune response, believed to be a key trigger of IBS symptoms.
These results suggest that inFoods IBS could be particularly beneficial for IBS-M patients, an underserved group for whom there are currently no FDA-approved drug treatments. IBS-M patients are estimated to represent approximately 33% of the IBS market. CEO Zack Irani-Cohen stated that this publication marks a major milestone in precision nutrition as a non-drug treatment pathway for IBS, offering a data-driven path to help patients reduce symptoms by identifying specific problematic foods.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.